UCB, Teva, Novartis, Pfizer and TransCelerate Biopharma win industry recognition at the eyeforpharma Philadelphia Awards 2016

eyeforpharma 2 - 3 May 2016, Philadelphia, USA.
The 2016 eyeforpharma Philadelphia Awards saw 22 finalists, with representation from every top 20 pharma, showcase the breadth of innovation within the industry. Submissions displayed cutting-edge application of new strategies for old problems.

Teva won the Most Valuable HCP or Healthcare Initiative with their foray into Artificial Intelligence. Teva presented "ASK Claire", an Intelligent Virtual Health Assistant that engages Multiple sclerosis (MS) patients on the web and in an app.

UCB picked up the Most Valuable Patient Initiative or Service Award with their Report Cards submission. The team presented an intriguing approach to create new incentives for decision makers to prioritise innovative therapies for Epilepsy Patients, by creating transparency into current care outcomes.

Individual leaders were also recognized for their refusal to accept the status quo, showing the way for the industry to progress. Chrisi Shaw, the, U.S. Country Head and President of Novartis picked up the Lifetime Achievement Award for her leadership on gender equality and contributions to patient-centricity throughout the pharma lifecycle.

Pfizer's Dennis Freire was awarded for his contributions towards patient-centric clinical trials with the Customer Innovator Award. Through a collaboration with ICON Firecrest collaboration, Freire oversaw a radical re-think of the onerous procedures facing patient registrants for clinical trials.

The groundbreaking consortium of top 20 pharma TransCelerate was also recognized with the Most Valuable Pharma Collaboration award for the work they've achieved in unlocking innovation that benefits everyone in pharma. Through shared research partnerships and close regulatory coordination, they are redefining the boundaries of what is possible in cross-industry collaboration on issues of shared commercial, and patient-centric interest.

The awards reflect eyeforpharma's mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients. The winning projects were selected from hundreds of initiatives submitted from teams across the global, and determined by a judging panel of senior industry experts, and patient advocates.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...